Syngene eyes sweet spot as new modalities hog limelight
Syngene COO Bhalgat expects earnings growth to pick up from Jan-Mar
Syngene CEO On sub-dynamics as US Biotech funding finds new normal, ADC capabilities: Scrip (citeline.com)
Syngene aims to optimise inventory, working capital cycle, says CFO
CRDMOs in India to create local supply eco-system, asserts itself as a bio-pharma sourcing powerhouse
Behind the numbers: How Syngene’s CFO is pioneering growth during sombre times
“3 Key Trends” with Mahesh Bhalgat
Biologics will be a major contributor to our growth, says Syngene CEO Jonathan Hunt
The landscape of STEM has significantly transformed
Innovative tumour models spearhead cancer research advancements
